Patent 7537924 was granted and assigned to Biovex Limited on May, 2009 by the United States Patent and Trademark Office.
The present invention relates to clinical herpes simplex virus (HSV) isolates with improved oncolytic capabilities as compared to reference laboratory HSV strains. The present invention also relates to methods of producing HSV strains of the invention and to pharmaceutical compositions comprising a HSV strain of the invention.